Elafibranor has 4 known drug interactions based on U.S. FDA drug labeling data. 1 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Mao Inhibitors, Bile Acid Binding Resins, Oral Contraceptives. Patients taking Elafibranor should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 4
- Major
- 1
- Moderate
- 3
Major (1)
- Elafibranor + Mao Inhibitors— Co-administration may increase risk of myopathy and muscle injury. CPK elevation and myalgia occurred in patients on ELA…
Moderate (3)
- Elafibranor + Bile Acid Binding Resins— Bile acid sequestrants may reduce ELAFIBRANOR absorption and systemic exposure, decreasing efficacy.
- Elafibranor + Oral Contraceptives— ELAFIBRANOR is a weak CYP3A4 inducer that may reduce systemic exposure of progestin and ethinyl estradiol, potentially l…
- Elafibranor + Rifampin— Rifampin induces metabolizing enzymes, reducing systemic exposure of elafibranor and its active metabolite, potentially …